Sign In
Buy DD
DuPont de Nemours Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.488 |
| EPS actual | $0.550 |
| EPS Surprise | 12.68% |
| Revenue estimate | 1.666B |
| Revenue actual | 1.681B |
| Revenue Surprise | 0.92% |
| Release date | Feb 10, 2026 |
| EPS estimate | $0.430 |
| EPS actual | $0.460 |
| EPS Surprise | 6.98% |
| Revenue estimate | 1.688B |
| Revenue actual | 1.693B |
| Revenue Surprise | 0.284% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.466 |
| EPS actual | $1.09 |
| EPS Surprise | 134.11% |
| Revenue estimate | 2.901B |
| Revenue actual | 3.072B |
| Revenue Surprise | 5.89% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.445 |
| EPS actual | $1.12 |
| EPS Surprise | 151.69% |
| Revenue estimate | 3.24B |
| Revenue actual | 3.257B |
| Revenue Surprise | 0.527% |
Last 4 Quarters for DuPont de Nemours
Below you can see how DD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 05, 2025 |
| Price on release | $30.38 |
| EPS estimate | $0.445 |
| EPS actual | $1.12 |
| EPS surprise | 151.69% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $30.21 |
| Jul 31, 2025 | $30.08 |
| Aug 01, 2025 | $29.26 |
| Aug 04, 2025 | $29.67 |
| Aug 05, 2025 | $30.38 |
| Aug 06, 2025 | $29.62 |
| Aug 07, 2025 | $29.66 |
| Aug 08, 2025 | $29.49 |
| Aug 11, 2025 | $29.25 |
| 4 days before | 0.554% |
| 4 days after | -3.72% |
| On release day | -2.48% |
| Change in period | -3.19% |
| Release date | Nov 06, 2025 |
| Price on release | $39.15 |
| EPS estimate | $0.466 |
| EPS actual | $1.09 |
| EPS surprise | 134.11% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $34.16 |
| Nov 03, 2025 | $34.69 |
| Nov 04, 2025 | $37.76 |
| Nov 05, 2025 | $39.63 |
| Nov 06, 2025 | $39.15 |
| Nov 07, 2025 | $39.80 |
| Nov 10, 2025 | $40.21 |
| Nov 11, 2025 | $40.40 |
| Nov 12, 2025 | $40.79 |
| 4 days before | 14.60% |
| 4 days after | 4.19% |
| On release day | 1.66% |
| Change in period | 19.40% |
| Release date | Feb 10, 2026 |
| Price on release | $49.43 |
| EPS estimate | $0.430 |
| EPS actual | $0.460 |
| EPS surprise | 6.98% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $47.83 |
| Feb 05, 2026 | $45.68 |
| Feb 06, 2026 | $46.73 |
| Feb 09, 2026 | $47.10 |
| Feb 10, 2026 | $49.43 |
| Feb 11, 2026 | $51.53 |
| Feb 12, 2026 | $49.43 |
| Feb 13, 2026 | $50.22 |
| Feb 17, 2026 | $50.87 |
| 4 days before | 3.35% |
| 4 days after | 2.91% |
| On release day | 4.25% |
| Change in period | 6.36% |
| Release date | May 05, 2026 |
| Price on release | $49.23 |
| EPS estimate | $0.488 |
| EPS actual | $0.550 |
| EPS surprise | 12.68% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $44.62 |
| Apr 30, 2026 | $45.66 |
| May 01, 2026 | $46.24 |
| May 04, 2026 | $45.43 |
| May 05, 2026 | $49.23 |
| May 06, 2026 | $50.06 |
| May 07, 2026 | $48.36 |
| May 08, 2026 | $49.76 |
| May 11, 2026 | $50.59 |
| 4 days before | 10.33% |
| 4 days after | 2.76% |
| On release day | 1.69% |
| Change in period | 13.38% |
DuPont de Nemours Earnings Call Transcript Summary of Q1 2026
DuPont delivered a stronger-than-expected start to 2026: Q1 net sales of $1.7B (up 4% YoY, 2% organic), operating EBITDA of $414M (up 15% YoY) and double-digit adjusted EPS growth. Organic growth was driven by Health Care & Water (notably medical packaging and biopharma) and aerospace; Diversified Industrials was roughly flat organically with weakness in construction offset by aerospace and automotive (EV battery adhesives). Margin expansion benefited from favorable mix (~50 bps) and productivity (~70 bps). Management raised full-year guidance (midpoint net sales ~$7.185B; operating EBITDA midpoint ~$1.745B; adjusted EPS $2.35–$2.40) and announced a $275M accelerated share repurchase under the existing program. Company expects to offset roughly $90M of incremental input/transportation costs (driven by the Middle East conflict) via pricing and surcharges, with most actions phased in starting May; free cash flow conversion target remains >90% for the year. The Aramids divestiture closed April 1 (~$1.1B net proceeds), contributing to interest income and balance sheet flexibility for buybacks or M&A. Near-term risks include Middle East logistics disruption (some Q1 shipments delayed, largely mitigated) and currency headwinds, but management emphasizes operational improvements, digital/AI investments, and continued focus on productivity and portfolio optimization (80/20 work in Diversified Industrials).
